MyNavCare Co-pay Program
Savings card from Genmab
Epkinly’s maker has a savings program. Its page doesn’t list a dollar amount.
From the maker’s site, checked November 2, 2026. Check the maker’s page for who can use it.
How to pay the least
Ask for the cash price
Epkinly
Epkinly is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.
- Ask your pharmacy for Epkinly’s cash price, and one or two other pharmacies too.
Compare every option
Question
Brand nameEpkinly
Authorized genericepcoritamab-bysp
Regular genericepcoritamab-bysp
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Epkinly?
The original
–
–
Details for each option
Details for
Brand nameThe maker’s card
Authorized genericNot sold
There isn’t one. An authorized generic is Epkinly itself, from the same company, sold without the brand name, and usually for less. For now Epkinly is the only choice; its maker’s savings card can lower what you pay.
Regular genericNot sold
Epkinly is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.
What it’s used for
What the FDA label says
EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated:
- For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- In combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
- As monotherapy for the treatment of adult patients with relapsed or refractory FL after two or more lines of systemic therapy.
Source: the FDA label for Epkinly (Genmab US, Inc.), June 22, 2026. Full label on DailyMed
Good to know
- “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Check the maker’s page for who can use it.
- Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
- Don’t stop or change a medicine without talking to your pharmacist or prescriber.
Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/epkinly/